Jo Vandesompele is a professor at Ghent University, Belgium and group leader at the Cancer Research Institute in Ghent where he co-supervises the OncoRNALab. He obtained a Master of Science in Bioscience Engineering and a PhD in Medical Genetics. He is author of more than 250 scientific articles, including some pioneering publications in the domain of RNA quantification and non-coding RNA. His H-index is 97, with 97 000 citations.

Jo is also co-founder of 3 companies, with roles as Chief Scientific Officer, including pxlence, InActiv Blue, and Biogazelle (now a CellCarta company).

Dr. Marzia Del Re works as an Assistant Professor in the Clinical Pharmacology and Pharmacogenetics Unit at the University of Pisa (Italy). Her research program is focused on the 1) diagnosis of adverse drug reactions by pharmacogenetic analysis of germline DNA and 2) monitoring of acquired resistance to targeted therapies using circulating nucleic acids released from tumors in plasma.

Dr. Del Re received her Pharm.D. degree in 2009 and became a Specialist in Clinical Biochemistry in 2014 at the University of Pisa. She obtained a Master’s degree in "Clinical trials in Oncology, Hematology and Internal Medicine" in 2015 and a Ph.D. title in Clinical Pathophysiology in 2018 at the University of Pisa.

Dr. Del Re received the Merit Awards from the American Society of Clinical Oncology (2011 and 2013) for her studies on DPYD variants and adverse drug reactions by fluoropyrimidines. Dr. Del Re received the Umberto Veronesi Foundation Fellowship (2012) for a project on pharmacogenetics of tamoxifen. Dr. Del Re was the recipient of a special award from the Italian Society of Pharmacology for her contribution to research in pharmacogenetics (2014) and the special award "SIF-Farmindustria for Pharmacological Research" (2016). In 2018, Dr. Del Re was awarded by the Italian Association of Medical Oncology (AIOM) for her research on circulating tumor DNA in lung cancer and in 2020 received the ESMO travel grant for the research “Ki67 expression and CDK4/6i activity: an emerging role for PIK3CA mutations in metastatic breast cancer patients”. In 2015, 2016, 2018 and 2019 Dr. Del Re worked for a total of 9 months at the Erasmus Medical Center, Rotterdam (Netherlands) as a Visiting Scientist, on projects revolving around drug resistance in prostate and lung cancer. In particular, she worked on exosomes isolation from plasma and RNA extraction, optimized the ddPCR assay and performed expression analyses on a large series of plasma samples. In 2017, Dr. Del Re worked at the NCI/NIH (Bethesda, USA) as a Visiting Scientist, on in vitro CRPC models.

From November 2022, Dr. Del Re works as a Visiting Professor at the Center for Thoracic Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Hospital, working on liquid biopsy in lung cancer; and in August 2023, Dr. Del Re joined the Early Drug Development Unit at the Memorial Sloan Kettering Cancer Center (New York).

Wim is a postdoctoral researcher at Ghent University with a decade of experience in digital PCR technology ranging from assay development to generating new data analysis algorithms. He has a special interest in the use of nucleic acid quantification to aid clinical and therapeutic decision-making and his main area of work has been in the field of infectious diseases/pathogen detection (HIV). He is the co-founder of the UGent Digital PCR consortium which has the goal to introduce dPCR to a broader audience, develop and share expertise on several of the commercial dPCR platforms and offer benchmark opportunities to evaluate cross-platform performance.

Before founding JETA, Mr. Bost was Director of Human Genetic and Transplantation Diagnostics R&D at Celera/Quest Diagnostics in the San Francisco Bay Area. Mr. Bost also spent many years developing novel PCR, DNA sequencing, and sample preparation technologies at Applied Biosystems, Roche Molecular Systems, and Cetus Corporation. Mr. Bost received his B.A. in Microbiology and Immunology from the University of California, Berkeley. He is also the primary inventor of multiple issued patents related to kits and methods for selective nucleic acid isolation.

The current research aims of Dr. Wang are to understand malaria parasite biology and mosquito infectivity, with an emphasis on developing novel vaccines for malaria. He also leads a molecular diagnosis team for malaria epidemiological studies and is working on developing novel vaccines for malaria. Moreover, he leads a molecular diagnosis team for malaria epidemiological studies.